The prognostic value of E-cadherin in gastric cancer: A meta-analysis

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2589-2596

  Xing, Xiangbin ^a   Tang, Yong Bo ^b   Yuan, Gang ^a   Wang, Yongfei ^c   Wang, Jinhui ^a   Yang, Yang ^a   Chen, Minhu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

E cadherin; gastric cancer; immunohistochemistry; prognosis

Indexed keywords

UVOMORULIN;

ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISTANT METASTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

CADHERINS; CASE-CONTROL STUDIES; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84875621521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27947     Document Type: Article

References (48)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Amedei A, Benagiano M, della Bella C, et al. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011; 2011: 437348.
3. Zhang QW, Liu L, Chen R, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 2903-8.
4. Yasui W, Hata J, Yokozaki H, et al. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 1988; 41: 211-17.
5. Deveci MS, Deveci G,. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007; 10: 112-16.
6. Fondevila C, Metges JP, Fuster J, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90: 206-15.
7. Goodwin M, Yap AS,. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J Mol Histol 2004; 35: 839-44.
8. Perl AK, Wilgenbus P, Dahl U, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-3.
9. Jeanes A, Gottardi CJ, Yap AS,. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27: 6920-9.
10. Graziano F, Arduini F, Ruzzo A, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol 2004; 15: 489-92.
11. Berx G, Becker KF, Höfler H, et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-37.
12. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41: 508-17.
13. Becker KF, Rosivatz E, Blechschmidt K, et al. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 2007; 185: 204-12.
14. Alves CC, Carneiro F, Hoefler H, et al. Role of the epithelial- mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009; 14: 3035-50.
15. Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol 2012; 19: S656-S664.
16. Carvalho J, van Grieken NC, Pereira PM, et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 2012; 228: 31-44.
17. Oka H, Shiozaki H, Kobayasi K, et al. Immunoreactive expression of E-cadherin in human gastric cancer: preliminary report. Nihon Geka Gakkai Zasshi 1990; 91: 1814.
18. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-19.
19. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
20. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
22. Bazas VM, Lukyanova NY, Demash DV, et al. Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer. Exp Oncol 2008; 30: 235-9.
23. Chen HC, Chu RY, Hsu PN, et al. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett 2003; 201: 97-106.
24. Chu YQ, Ye ZY, Tao HQ, et al. Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol 2008; 14: 1990-6.
25. Czyzewska J, Guzińska-Ustymowicz K, Ustymowicz M, et al. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem Cytobiol 2010; 48: 37-45.
26. Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer 1996; 69: 184-9.
27. Graziano F, Mandolesi A, Ruzzo A, et al. Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol 2004; 25: 106-10.
28. Hou F, Yuan W, Huang J, et al. Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol 2012; 29: 2691-700.
29. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997; 112: 46-54.
30. Joo YE, Park CS, Kim HS, et al. Prognostic significance of E-cadherin/catenin complex expression in gastric cancer. J Korean Med Sci 2000; 15: 655-66.
31. Kawanishi K, Doki Y, Shiozaki H, et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am J Clin Pathol 2000; 113: 266-74.
32. Kim JH, Park JM, Jung CW, et al. The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. J Surg Oncol 2008; 97: 125-30.
33. Kim MA, Lee HS, Lee HE, et al. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology 2009; 54: 442-51.
34. Lazǎr D, Tǎban S, Ardeleanu C, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival. Rom J Morphol Embryol 2008; 49: 459-67.
35. Saad AA, Awed NM, Abd Elkerim NN, et al. Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. Ann Surg Oncol 2010; 17: 3059-67.
36. Shimada Y, Yamasaki S, Hashimoto Y, et al. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res 2004; 10: 2818-23.
37. Shino Y, Watanabe A, Yamada Y, et al. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995; 76: 2193-201.
38. Silva EM, Begnami MD, Fregnani JH, et al. Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma. Gastric Cancer 2008; 11: 149-59.
39. Skarlos DV, Bai M, Goussia A, et al. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res 2007; 27: 2973-83.
40. Takagawa R, Akimoto K, Ichikawa Y, et al. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann Surg Oncol 2010; 17: 81-88.
41. Uchikado Y, Okumura H, Ishigami S, et al. Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer 2011; 14: 41-49.
42. Walch A, Seidl S, Hermannstädter C, et al. Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod Pathol 2008; 21: 544-52.
43. Yashiro M, Nishioka N, Hirakawa K,. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 2006; 42: 2397-403.
44. Yonemura Y, Nojima N, Kaji M, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76: 941-53.
45. Zhong XY, Zhang LH, Jia SQ, et al. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology 2008; 52: 560-8.
46. Liu WF, Ji SR, Sun JJ, et al. CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 2012; 13: 6399-406.
47. Park ES, Do IG, Park CK, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res 2009; 15: 291-8.
48. Egger M, Zellweger-Zähner T, Schneider M, et al. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350: 326-9.